Advertisement

IR Playbook pp 323-328 | Cite as

Prostate Artery Embolization

  • Timothy C. Huber
  • Benjamin N. Contrella
  • Andre Uflacker
Chapter

Abstract

Benign prostatic hyperplasia (BPH) is exceedingly common in men over 50 years of age. It can range from asymptomatic to severely symptomatic with obstruction and recurrent urinary tract infections. For men with symptomatic BPH who do not respond to medical therapy, prostate artery embolization is a minimally invasive treatment option. Selective arterial embolization of the arteries supplying the prostate effectively reduces both the volume of the prostate and the associated symptoms. Additionally, prostate artery embolization can be used to treat hematuria of prostatic origin.

Keywords

Benign prostatic hypertrophy Prostate Prostate artery embolization Prostate anatomy Pelvic anatomy 

References

  1. 1.
    Edwards JL. Diagnosis and management of benign prostatic hyperplasia. Am Fam Physician. 2008;77(10):1403–10.PubMedGoogle Scholar
  2. 2.
    Carson C III, Rittmaster R. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology. 2003;61(4, Supplement 1):2–7.  https://doi.org/10.1016/S0090-4295(03)00045-1.CrossRefPubMedGoogle Scholar
  3. 3.
    Wilson JD, Roehrborn C. Long-term consequences of castration in men: lessons from the Skoptzy and the eunuchs of the Chinese and Ottoman courts. J Clin Endocrinol Metab. 1999;84(12):4324–31.  https://doi.org/10.1210/jcem.84.12.6206.CrossRefPubMedGoogle Scholar
  4. 4.
    Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132(3):474–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Sarma AV, Wei JT. Benign prostatic hyperplasia and lower urinary tract symptoms. N Engl J Med. 2012;367(3):248–57.  https://doi.org/10.1056/NEJMcp1106637.CrossRefPubMedGoogle Scholar
  6. 6.
    Roehrborn CG. Benign prostatic hyperplasia: an overview. Rev Urol. 2005;7(Suppl 9):S3–S14.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol. 2003;44(6):637–49.CrossRefPubMedGoogle Scholar
  8. 8.
    McNeal JE. The zonal anatomy of the prostate. Prostate. 1981;2(1):35–49.  https://doi.org/10.1002/pros.2990020105.CrossRefPubMedGoogle Scholar
  9. 9.
    Guneyli S, Ward E, Thomas S, Yousuf AN, Trilisky I, Peng Y, et al. Magnetic resonance imaging of benign prostatic hyperplasia. Diagn Interv Radiol. 2016;22(3):215–9.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Verma S, Rajesh A. A clinically relevant approach to imaging prostate cancer: review. Am J Roentgenol. 2011;196(3_supplement):S1–S10.  https://doi.org/10.2214/AJR.09.7196.CrossRefGoogle Scholar
  11. 11.
    Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3:524–48.  https://doi.org/10.1001/jamaoncol.2016.5688.CrossRefPubMedGoogle Scholar
  12. 12.
    Bischoff W, Goerttler U. Successful intra-arterial embolization of bleeding carcinoma of the prostate. UrologeAusg A. 1977;16(2):99–102.Google Scholar
  13. 13.
    Bilhim T, Pereira JA, Fernandes L, Tinto HR, Pisco JM. Angiographic anatomy of the male pelvic arteries. Am J Roentgenol. 2014;203(4):W373–82.  https://doi.org/10.2214/AJR.13.11687.CrossRefGoogle Scholar
  14. 14.
    McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011;185(5):1793–803.  https://doi.org/10.1016/j.juro.2011.01.074.CrossRefPubMedGoogle Scholar
  15. 15.
    Moyer VA. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(2):120.  https://doi.org/10.7326/0003-4819-157-2-201207170-00459.CrossRefPubMedGoogle Scholar
  16. 16.
    Bilhim T, Tinto HR, Fernandes L, Pisco JM. Radiological anatomy of prostatic arteries. Tech Vasc Interv Radiol. 2012;15(4):276–85.  https://doi.org/10.1053/j.tvir.2012.09.006.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Yamaki K-I, Saga T, Doi Y, Aida K, Yoshizuka M. A statistical study of the branching of the human internal iliac artery. Kurume Med J. 1998;45(4):333–40.  https://doi.org/10.2739/kurumemedj.45.333.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Golzarian J, Antunes AA, Bilhim T, Carnevale FC, Konety B, McVary KT, et al. Prostatic artery embolization to treat lower urinary tract symptoms related to benign prostatic hyperplasia and bleeding in patients with prostate cancer: proceedings from a Multidisciplinary Research Consensus Panel. J Vasc Interv Radiol. 2014;25(5):665–74.  https://doi.org/10.1016/j.jvir.2013.11.003.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Loffroy R, Pottecher P, Cherblanc V, Favelier S, Estivalet L, Koutlidis N, et al. Current role of transcatheter arterial embolization for bladder and prostate hemorrhage. Diagn Interv Imaging. 2014;95(11):1027–34.  https://doi.org/10.1016/j.diii.2014.03.008.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Lepor H. Medical treatment of benign prostatic hyperplasia. Rev Urol. 2011;13(1):20–33.PubMedPubMedCentralGoogle Scholar
  21. 21.
    McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349(25):2387–98.  https://doi.org/10.1056/NEJMoa030656.CrossRefPubMedGoogle Scholar
  22. 22.
    DeMeritt JS, Elmasri FF, Esposito MP, Rosenberg GS. Relief of benign prostatic hyperplasia-related bladder outlet obstruction after transarterial polyvinyl alcohol prostate embolization. J Vasc Interv Radiol. 2000;11(6):767–70.  https://doi.org/10.1016/S1051-0443(07)61638-8.CrossRefPubMedGoogle Scholar
  23. 23.
    Uflacker A, Haskal ZJ, Bilhim T, Patrie J, Huber T, Pisco JM. Meta-analysis of prostatic artery embolization for benign prostatic hyperplasia. J Vasc Interv Radiol. 2016;27(11):1686–1697.e8.  https://doi.org/10.1016/j.jvir.2016.08.004.CrossRefPubMedGoogle Scholar
  24. 24.
    Kuang M, Vu A, Athreya S. A meta-analysis of prostatic artery embolization in the treatment of symptomatic benign prostatic hyperplasia. J Vasc Interv Radiol. 2016;27(3):S53.  https://doi.org/10.1016/j.jvir.2015.12.147.CrossRefGoogle Scholar
  25. 25.
    Cizman Z, Isaacson A, Burke C. Short- to midterm safety and efficacy of prostatic artery embolization: a systematic review. J Vasc Interv Radiol. 2016;27(10):1487–1493.e1.  https://doi.org/10.1016/j.jvir.2016.04.015.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Timothy C. Huber
    • 1
  • Benjamin N. Contrella
    • 1
  • Andre Uflacker
    • 1
  1. 1.University of Virginia Health System, Department of Radiology and Medical ImagingCharlottesvilleUSA

Personalised recommendations